MedPath

Mobile Psychosocial Interventions for MMT Clients

Not Applicable
Conditions
Opioid Abuse
Substance Abuse
Interventions
Behavioral: standard treatment
Behavioral: mobile control
Behavioral: MTS (Mobile Therapeutic System)
Registration Number
NCT01632982
Lead Sponsor
National Development and Research Institutes, Inc.
Brief Summary

This study will develop and evaluate the preliminary efficacy and cost-effectiveness of a mobile phone-delivered psychosocial intervention for opioid-dependent adults (N=219) in methadone maintenance treatment (MMT). A three-arm, randomized clinical trial will evaluate the relative efficacy of: (1) standard MMT; (2) standard MMT plus the mobile intervention; and (3) a mobile-based control condition on the primary outcomes of treatment retention and opioid use (assessed via urine toxicology). If results are promising, this novel therapeutic tool may have a tremendous impact on improving access to and effectiveness of substance abuse treatment in a variety of other populations (and could also be adapted for an array of other behavioral health applications), while significantly limiting costs.

Detailed Description

This study will develop and implement a mobile technology-delivered psychosocial intervention for opioid-dependent adults in methadone maintenance treatment (MMT). This novel therapeutic system promises to be cost-effective and to enable the provision of flexible, on-demand therapeutic support outside of the formal treatment setting. The specific aims of this investigation are as follows: Aim 1: The investigators will develop a novel, interactive, evidence-based psychosocial intervention delivered via mobile phones, designed to promote skills acquisition and reduce illicit drug use. Specifically, our Mobile Therapeutic System (MTS) will offer key elements of a psychosocial intervention for substance use disorders of known efficacy (the Community Reinforcement Approach). Participants will be provided with unlimited daily prompts to encourage use of the program and will be able to access the application at any time and as much as they choose, within their natural environments. Our iterative development process will include input from focus groups with clients in methadone treatment (n=24), input from experts in the field, and feedback testing of a beta-version of the mobile phone-based program with clients in methadone treatment (n=30). Aim 2: The investigators will evaluate the efficacy of this mobile tool with participants entering MMT during the first three months of their treatment (n=219). The investigators will evaluate the relative preliminary efficacy of (1) standard treatment, (2) standard treatment plus MTS and (3) a mobile-based control condition on the primary outcomes of retention and opioid use (via urine toxicology) and secondary outcomes of other substance use (via urine toxicology and self-report), readiness to change drug use behavior, coping skills, opioid craving, HIV risk behavior, and psychosocial functioning during the 3-month intervention phase. Durability of effects will be examined at 1 and 3 month follow-ups. Aim 3: The investigators will perform an economic analysis of MTS in community-based MMT. The investigators will estimate the incremental costs and the incremental cost-effectiveness ratio (ICER) of MTS relative to standard care and the mobile control group. The primary ICER will be the incremental costs per increased abstinence time (the clinical measure of effectiveness) and the secondary ICER will be incremental costs per increased quality adjusted life year (QALY) (the economic measure of effectiveness). Cost data will be vital to future translational projects to disseminate effective mobile interventions in community systems. If results are promising, this novel therapeutic tool may have a tremendous impact on improving access to and effectiveness of substance abuse treatment in a variety of other populations (and could also be adapted for an array of other behavioral health applications), while significantly limiting costs.

Recruitment & Eligibility

Status
UNKNOWN
Sex
All
Target Recruitment
219
Inclusion Criteria
  • client enrolled in the study site's methadone maintenance program
  • within the first month of initiating methadone maintenance treatment
  • 18 years of age or older
  • sufficient English-language ability to participate in informed consent process, complete study assessments and understand the text in mobile phone- delivered interventions
Exclusion Criteria
  • entering treatment at the study site with the intention of receiving a methadone-assisted withdrawal only
  • evidence of an active psychiatric disorder requiring immediate intervention (e.g., suicidality, psychosis)
  • evidence of significant mental illness that may preclude participation

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
standard treatmentstandard treatmentthe standard drug counseling offered to patients in methadone maintenance treatment at the study site
Mobile Therapeutic System (MTS)standard treatmentThe Mobile Therapeutic System (MTS) is a novel, interactive, mobile phone-delivered psychosocial intervention designed to promote skills acquisition and reduce drug use among adults in methadone maintenance treatment
mobile controlmobile controla mobile phone-based application that directs participants to the NIDA website's home page
mobile controlstandard treatmenta mobile phone-based application that directs participants to the NIDA website's home page
Mobile Therapeutic System (MTS)MTS (Mobile Therapeutic System)The Mobile Therapeutic System (MTS) is a novel, interactive, mobile phone-delivered psychosocial intervention designed to promote skills acquisition and reduce drug use among adults in methadone maintenance treatment
Primary Outcome Measures
NameTimeMethod
opioid use6 months

participants' illicit use of opioids, as measured by urine toxicology and self-report (self-report data collected via the timeline follow-back calendar assessment \[TLFB\])

treatment retention6 months

participants' retention in methadone maintenance treatment (MMT)

Secondary Outcome Measures
NameTimeMethod
HIV risk behavior6 months

participants' HIV risk behavior as measured by the High Risk-Taking Behavior Scale (HRBS)

other substance use6 months

participants' use of alcohol and drugs, as measured by urine toxicology and self-report (self-report data collected via the timeline follow-back calendar assessment \[TLFB\])

heroin/opioid craving6 months

participants' craving for heroin and/or other opioids, as measured by the Heroin/Opiate Craving Questionnaire (HCQ)

psychiatric and psychosocial functioning6 months

participants' level of psychiatric functioning (as assessed by the Brief Symptom Inventory \[BSI\]) and psychosocial functioning (as assessed by the Addiction Severity Index \[ASI\])

coping skills6 months

participants' coping skills as measured by the Coping Strategies Scale (CSS)

readiness to change drug use6 months

participants' readiness to change drug use, as measured by the Stages of Change Readiness and Treatment Eagerness Scale (SOCRATES)

Trial Locations

Locations (1)

Bridge Plaza Treatment and Rehabilitation Clinic

🇺🇸

Long Island City, New York, United States

© Copyright 2025. All Rights Reserved by MedPath